Eisai ‘speechless’ after another Fycompa price smack-down from Germany

Carly Helfand Germany's cost-effectiveness gatekeepers have delivered another blow to Eisai over the price of Fycompa. And the verdict, just the drugmaker's latest frustration ...

Allergan loses fight to block Ackman from voting for a Valeant takeover

Carly Helfand Valeant and partner Bill Ackman have dodged a serious roadblock in their quest to acquire Allergan. A 9.7% roadblock, if you will. FiercePharma News

Bristol-Myers’ 91-country hep C access plan still draws fire from price critics

Carly Helfand Bristol-Myers Squibb is taking Gilead's lead when it comes to developing-world access for its hepatitis C drug, offering up a tiered pricing strategy and licensing ...

Like Novartis before it, AstraZeneca benefits big time from Ranbaxy issues

Eric Palmer Ranbaxy Laboratories in June finally managed to finesse its regulatory problems enough to get a generic of Novartis' Diovan to market, boosting its own fortunes while ...

Scripps cancer spinout Xcovery grabs $20M from a pharma partner in China

John Carroll Chris Liang had already forged a compelling profile in drug development when the newly formed Scripps Florida recruited him as head of chemistry back in 2004. Liang, who ...

If Teva wanted a clear sign from Supreme Court on Copaxone, no such luck

Carly Helfand Teva's been waiting a long time to get its Copaxone patent appeal before the Supreme Court. And now that the court has heard oral arguments, it seems to be divided ...

Genentech tightens distribution on top cancer meds, triggering blowback from hospitals

Tracy Staton Roche's Genentech unit is getting some high-profile blowback from a change to its distribution model on three top cancer meds. Hospital and pharmacy executives claim ...

Still reeling from China bribery probe, GSK faces corruption scandal in Syria

Arlene Weintraub The British company said Thursday that it had received an email containing allegations from a whistleblower pertaining to bribes paid by GSK's consumer healthcare ...

FedEx indicted for delivering drugs to addicts from illegal web pharmacies

Eric Palmer FedEx has received a special delivery from the U.S. Department of Justice (DoJ), a 15-count indictment accusing it of being the delivery vehicle of choice for a certain ...

Concert’s spasticity drug gets out from under an FDA hold

Damian Garde The FDA has lifted a partial clinical hold on Concert Pharmaceuticals' treatment for spasticity, allowing the biotech to resume dosing in a Phase I trial. FierceBiotech ...

U-turn from U.K.’s NICE boosts Biogen’s high-flying Tecfidera

Carly Helfand Biogen Idec's multiple sclerosis pill Tecfidera has been steamrolling since it hit the U.S. market last April. And now, it's poised to pad global sales with a ...

EMA approves 39 drugs in H1, down from 44 last year

Eric Palmer The European Medicines Agency approved 39 new drugs in the first half of the year, PharmaTimes reports. FiercePharma News
Page 3 of 1412345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS